Nothing Special   »   [go: up one dir, main page]

Latest News for: Gilead Sciences

Edit

MASH Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, MOA, ROA ...

GetNews 11 Feb 2025
... Hepion Pharmaceuticals, Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences, Ionis Pharmaceuticals, Corcept Therapeutics, and others ... Gilead Sciences PXL065.
Edit

KITE PRESENTS NEW DATA ON PATIENT OUTCOMES WITH CAR T-CELL THERAPY AT THE 7TH EUROPEAN CAR T-CELL MEETING, 6-8 FEBRUARY, STRASBOURG, FRANCE

Pharmiweb 10 Feb 2025
Stockley Park, UK – 6 February 2025 – Kite, a Gilead Company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) ... About Gilead Sciences. Gilead Sciences, Inc.
Edit

UN AIDS chief warns HIV cases could surge without US support

The Times of India 10 Feb 2025
The twice-yearly shot, developed by US-based Gilead Sciences and sold as Sunlenca, has shown complete protection against HIV in women and is highly effective in men.International aid, Byanyima pointed ...
Edit

BTK inhibitors Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Patient Pool, Drugs, ...

GetNews 10 Feb 2025
Tirabrutinib, an oral small molecule developed by Ono Pharmaceutical and Gilead Sciences, functions as a Bruton's tyrosine kinase (BTK) inhibitor intended for treating autoimmune disorders and hematological malignancies.
Edit

Georgia leads in U.S. HIV cases. Here’s why the lifesaving drug PrEP faces barriers in ...

Chatanooga Times Free Press 08 Feb 2025
... who is an epidemiology professor at Emory University and leads AIDSVu and PrEPVu, which track HIV data and access to the drug — work that is backed by Gilead Sciences, a PrEP drug manufacturer.
Edit

CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Treatment Market 2034: EMA, PDMA, FDA Approvals, Prevalence, ...

GetNews 06 Feb 2025
CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Companies are Gilead Sciences, Novartis, Autolus Therapeutics, Cellectis, Guangzhou Bio-gene Technology, ... Gilead Sciences KYMRIAH (tisagenlecleucel).
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Gilead Sciences Inc)

Public Technologies 06 Feb 2025
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10 ... 2 ... GILEAD SCIENCES, INC ... GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE 3 ... GILEAD SCIENCES, INC ... Gilead Sciences Inc.
Edit

Thermo Fisher Scientific Accelerates 100 Percent Renewable Electricity Goal for European Operations with New Solar Power Agreement with X-ELIO

Pharmiweb 05 Feb 2025
The aggregated share of Lorca solar will simultaneously reduce Scope 2 and Scope 3 emissions for Thermo Fisher and the cohort of value chain partners—GSK, Gilead Sciences and Haleon—who participated ...
Edit

Gilead Submits Marketing Authorization Applications to European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention (Gilead Sciences Inc)

Public Technologies 04 Feb 2025
Foster City, Calif., February 3, 2025 - Gilead Sciences, Inc ... For more information about Gilead, please visit the company's website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences) ... Gilead Sciences Inc.
Edit

Global Oral Controlled Release Drug Delivery Technology Market is anticipated to reach USD 84.2 Billion by 2035

Pharmiweb 04 Feb 2025
Oral Controlled Release Drug Delivery Technology Market ... According to market projections, the industry will expand at a compound annual growth rate (CAGR) of 7.2% over the forecast period (2025–2035) ... Inc ... F ... Sun Pharmaceuticals BioNTech Gilead Sciences.
Edit

Marginal Zone Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | ...

GetNews 03 Feb 2025
Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others ... Gilead Sciences.
Edit

We have a shot at ending HIV — don’t let politics get in the way

The Hill 01 Feb 2025
lenacapavir, recently named Science Magazine's 2024 "Drug of the Year.". Lenacapavir, developed by Gilead Sciences, represents a groundbreaking leap in HIV prevention ... First, Gilead should expand its licensing agreement to include all countries.
Edit

Topical Mupirocin Lowers Lupus Inflammation

Mega Doctor News 30 Jan 2025
Mega Doctor News ... J ... Aditum Bio; Anaptys Bio; AstraZeneca, PLC; Biogen; EMD Serono; Exo Therapeutics; Gilead Science, Inc.; GSK; Lilly, Eli, and Company; Lupus Research Alliance; Related Science, LLC; Rome Therapeutics; Synthekine; Ventus Therapeutics.

Most Viewed

×